Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Innate Pharma (IPHA) Invested Capital (2017 - 2025)

Historic Invested Capital for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $50.0 million.

  • Innate Pharma's Invested Capital fell 2805.6% to $50.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $50.0 million, marking a year-over-year decrease of 2805.6%. This contributed to the annual value of $43.1 million for FY2024, which is 5658.56% down from last year.
  • Latest data reveals that Innate Pharma reported Invested Capital of $50.0 million as of Q2 2025, which was down 2805.6% from $59.7 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Invested Capital peaked at $50622.0 billion during Q4 2021, and registered a low of $50.0 million during Q2 2025.
  • In the last 5 years, Innate Pharma's Invested Capital had a median value of $98.8 million in 2023 and averaged $10414.3 billion.
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 2682099208.95% in 2021, then tumbled by 9999.98% in 2023.
  • Innate Pharma's Invested Capital (Quarter) stood at $50622.0 billion in 2021, then dropped by 14.85% to $43106.5 billion in 2022, then plummeted by 100.0% to $98.8 million in 2023, then tumbled by 39.59% to $59.7 million in 2024, then decreased by 16.12% to $50.0 million in 2025.
  • Its last three reported values are $50.0 million in Q2 2025, $59.7 million for Q4 2024, and $69.6 million during Q2 2024.